Chinese Brands Are Taking Over Brazil — And It's Just Getting Started 
BHP's Incoming CEO Visits China Amid Pricing Dispute with CMRG 
Anthropic Fights Pentagon Blacklisting in Dual Federal Court Battles 
Disney Plans to Cut 1,000 Jobs Amid Ongoing Restructuring Efforts 
FedEx Pilots and Union Reach Tentative Agreement on 40% Pay Increase 
Pony.ai, Uber, and Verne Launch Europe's First Commercial Robotaxi Service in Zagreb 
Pilots Fear Retaliation for Refusing Middle East Flights Amid Ongoing Conflict 
Foreign Investors Pour $18.65 Billion into Japanese Stocks Amid Market Stabilization 
MATCH Act: How New U.S. Chip Legislation Could Freeze China's Semiconductor Ambitions 
Chinese Cars in Europe: Consumer Trust Is Shifting Fast 
Rio Tinto's California Boron Assets Attract Over a Dozen Bidders, Valued at Up to $2 Billion 
Anthropic's Mythos AI Model Sparks Emergency Cybersecurity Meeting With Top U.S. Bank CEOs 
SanDisk Joins Nasdaq-100, Replacing Atlassian on April 20 
Chalco Stock Surges as Q1 2025 Profit Forecast Jumps Up to 58% 
Bank of America Identifies Top Asia-Pacific Semiconductor Stocks Poised for AI-Driven Growth 
Bendigo and Adelaide Bank Posts Strong Q3 Earnings, Announces AI-Driven Job Cuts 
Lumentum Holdings Rides AI Wave With Order Book Filled Through 2028 
NEW YORK, Aug. 28, 2017 -- PHI Group, Inc., (www.phiglobal.com) (OTCQB:PHIL), a company focused on mergers and acquisitions and investments in natural resources, energy, agriculture, healthcare and special situations, announced today that it has formed PHIVITAE Corp., a Wyoming corporation, to serve as a holding subsidiary of the Company for pharmaceutical and healthcare-related business and signed a Letter of Intent (“LOI”) to acquire 80% of a 20-year old profitable European company that is engaged in pharmaceutical and medical device distribution.
According to the LOI, the Company will enter into a definitive purchase and sale agreement with the European target and will make cash payments for the purchase price, which will be finalized after completion of ongoing due diligence.
The Company intends to use the European target as a platform to distribute prized organic medicines developed by Tho Xuan Duong JSC, a company recognized by Guinness World Records with nearly four centuries of history in Vietnamese traditional medicine and herbs (www.thoxuanduong.com). It will also distribute FDA-cleared innovative medical devices using Low Level Laser Light Therapy technologies developed by American Laser Healthcare Corp, a Delaware corporation (Youtube: Mac Beam Inc), and other selective pharmaceutical products to the European markets.
The Company will announce further details after the signing of the definitive purchase and sale agreement and plans to close this transaction in six to eight weeks.
Henry Fahman, CEO of PHI Group, said, “We are very excited to acquire a majority interest in this European target which can serve as a platform to provide a variety of prized pharmaceutical products and medical devices to European countries and other geographical areas. The conclusion of this transaction will allow us to immediately consolidate its revenues and profits, which will potentially help our top and bottom lines as well as enhance our valuation in the market.”
About PHI Group
PHI Group (www.phiglobal.com) primarily focuses on mergers and acquisitions and invests in select industries and special situations that may substantially enhance shareholder value. PHI Group also provides M&A and consulting services through its wholly owned subsidiary, PHI Capital Holdings, Inc. (www.phicapitalholdings.com)
Safe Harbor
This news release contains forward-looking statements that are subject to certain risks and uncertainties that may cause actual results to differ materially from those projected on the basis of such forward-looking statements pursuant to the “safe-harbor” provisions of the Private Securities Litigation Reform Act of 1995.
Press Contact: Henry Fahman +1-702-475-5430 [email protected]
